tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Disc Medicine price target raised to $120 from $112 at BMO Capital

BMO Capital raised the firm’s price target on Disc Medicine (IRON) to $120 from $112 and keeps an Outperform rating on the shares. The myelofibrosis, MF, anemia key opinion leader event gives a comprehensive look at the treatment landscape and how Disc Medicine remains early but differentiated, the analyst tells investors in a research note. Following the event and the firm’s recent Phase 3 INDEPENDENCE luspaterecpt data preview, BMO is more encouraged by DISC-0974’s value and its positioning in MF anemia as DISC-0974 has shown potential to be used as a monotherapy, the firm added.

Elevate Your Investing Strategy:

  • Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1